Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 29, 2023
Product Development
Aug. 29 Quick Takes: Phase III miss in DMD for FibroGen
Plus: Expanded label for BMS’s Reblozyl, Apellis restructuring and updates from Inhibrx, CEPI, iCamuno, Regeneron, Nevia
BioCentury | Jul 1, 2021
Finance
June 30 Quick Takes: Beam looks to complement Apellis; plus Intellia, Aerovate, Hutchmed, Spero-Pfizer and more
Beam Therapeutics Inc. (NASDAQ:BEAM) unveiled a five-year partnership with Apellis Pharmaceuticals Inc. (NASDAQ:APLS) to collaborate on up to six research programs against complement system targets,
BioCentury | Jun 5, 2021
Targets & Mechanisms
Going beyond genetic medicines for muscular dystrophy
Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Jun 11, 2020
Product Development
J&J picks up pace for Warp Speed COVID-19 vaccine
Corning to produce glass packaging for countermeasures; plus progress on host-targeted therapies
BioCentury | May 1, 2020
Product Development
April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor
BioCentury | Jan 25, 2020
Emerging Company Profile
Aluda: targeting the fundamentals
Aluda begins to unveil pipeline, starting with first-in-class anti-VIM program for fibrosis
BioCentury | Jun 28, 2019
Clinical News
June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more
BioCentury | Aug 17, 2018
Clinical News
RXi's subretinal fibrosis therapy well tolerated in Phase I/II
Items per page:
1 - 10 of 105